Insulin degludec/insulin aspart (Ryzodeg, Novo Nordisk) administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Insulin degludec/insulin aspart (Ryzodeg, Novo Nordisk) administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
In the 26-week randomized multinational phase 3b trial, patients previously treated with basal insulin were randomly assigned to a regimen of either twice-daily Ryzodeg, or a basal-bolus regimen of once-daily insulin degludec plus 2 to 4 injections of insulin aspart.
The study did not meet its primary end point of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to 7.0% and 6.8% respectively, with no significant difference between the 2 regimens.
Patients who received Ryzodeg experienced a numerically lower rate of overall and nocturnal confirmed hypoglycemic episodes, 19% and 20% less, respectively.
The study was designed to investigate 2 different regimens for patients on basal insulin who need mealtime intensification. The results show that Ryzodeg could potentially be a simple alternative to basal-bolus therapy, as it delivers successful reduction in A1C with fewer injections than a basal-bolus regimen.
"Patients currently using basal-bolus regimens may need to take up to 4 daily injections, which can be a great burden and very inconvenient," said Dr Helena Rodbard, the study’s principal investigator and endocrinologist in Rockville, Md., in a press release. "This new treatment offers the potential for a simple alternative to basal-bolus for patients who require intensification of basal insulin regimens.”
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More